M Evans

Summary

Country: UK

Publications

  1. pmc Pioglitazone in clinical practice: where are we now?
    Joytish Govindan
    Department of Diabetes, University Hospital Llandough, Cardiff, Wales, UK
    Diabetes Ther 3:1-8. 2012
  2. pmc Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries
    Marc Evans
    Department of Diabetes, University Hospital Llandough, Llandough Hospital, Penlan Road, Cardiff, Penarth CF64 2XX, UK
    Health Qual Life Outcomes 11:90. 2013
  3. pmc A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice
    Marc Evans
    University Hospital Llandough, Penlan Road, Llandough, Penarth, South Glamorgan, UK
    Diabetes Ther 4:27-40. 2013
  4. doi request reprint Linagliptin as add-on therapy for type 2 diabetes - an overview
    D X Brown
    University Hospital Llandough, Wales, UK
    Drugs Today (Barc) 48:645-54. 2012
  5. ncbi request reprint The myotoxicity of statins
    Marc Evans
    Department of Diabetes and Endocrinology, University Hospital of Wales, Heath Park, Cardiff, UK
    Curr Opin Lipidol 13:415-20. 2002
  6. ncbi request reprint The future direction of cholesterol-lowering therapy
    Marc Evans
    Department of Metabolic Medicine, University Hospital of Wales, Cardiff, UK
    Curr Opin Lipidol 13:663-9. 2002
  7. ncbi request reprint Medical lipid-regulating therapy: current evidence, ongoing trials and future developments
    Marc Evans
    Department of Metabolic Medicine, Diabetes and Endocrinology, University of Wales College of Medicine, Cardiff, Wales
    Drugs 64:1181-96. 2004
  8. pmc A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
    M Evans
    Department of Medicine, University Hospital of Wales, Cardiff, UK
    Diabetes Obes Metab 13:677-84. 2011
  9. ncbi request reprint Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
    M Evans
    Cardiovascular Sciences Research Group, University Hospital of Wales, Cardiff, UK
    Circulation 101:1773-9. 2000
  10. doi request reprint A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
    P McEwan
    Cardiff Research Consortium, Cardiff, UK
    Diabetes Obes Metab 12:623-30. 2010

Collaborators

Detail Information

Publications16

  1. pmc Pioglitazone in clinical practice: where are we now?
    Joytish Govindan
    Department of Diabetes, University Hospital Llandough, Cardiff, Wales, UK
    Diabetes Ther 3:1-8. 2012
    ..In this review, the authors focus on putting the true risk-benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence...
  2. pmc Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries
    Marc Evans
    Department of Diabetes, University Hospital Llandough, Llandough Hospital, Penlan Road, Cardiff, Penarth CF64 2XX, UK
    Health Qual Life Outcomes 11:90. 2013
    ..We examined the respective disutility associated with a single event of daytime, nocturnal, severe and non-severe hypoglycaemia...
  3. pmc A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice
    Marc Evans
    University Hospital Llandough, Penlan Road, Llandough, Penarth, South Glamorgan, UK
    Diabetes Ther 4:27-40. 2013
    ....
  4. doi request reprint Linagliptin as add-on therapy for type 2 diabetes - an overview
    D X Brown
    University Hospital Llandough, Wales, UK
    Drugs Today (Barc) 48:645-54. 2012
    ..It therefore represents a major advancement in the pharmacotherapy of patients with T2D...
  5. ncbi request reprint The myotoxicity of statins
    Marc Evans
    Department of Diabetes and Endocrinology, University Hospital of Wales, Heath Park, Cardiff, UK
    Curr Opin Lipidol 13:415-20. 2002
    ....
  6. ncbi request reprint The future direction of cholesterol-lowering therapy
    Marc Evans
    Department of Metabolic Medicine, University Hospital of Wales, Cardiff, UK
    Curr Opin Lipidol 13:663-9. 2002
    ....
  7. ncbi request reprint Medical lipid-regulating therapy: current evidence, ongoing trials and future developments
    Marc Evans
    Department of Metabolic Medicine, Diabetes and Endocrinology, University of Wales College of Medicine, Cardiff, Wales
    Drugs 64:1181-96. 2004
    ..In addition, the pleiotropic anti-inflammatory effects of lipid lowering therapy may provide further risk reduction...
  8. pmc A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
    M Evans
    Department of Medicine, University Hospital of Wales, Cardiff, UK
    Diabetes Obes Metab 13:677-84. 2011
    ..Enhancing the pharmacological predictability and extending the duration of action could simplify insulin titration and further reduce the incidence of hypoglycaemia...
  9. ncbi request reprint Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
    M Evans
    Cardiovascular Sciences Research Group, University Hospital of Wales, Cardiff, UK
    Circulation 101:1773-9. 2000
    ..Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus...
  10. doi request reprint A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
    P McEwan
    Cardiff Research Consortium, Cardiff, UK
    Diabetes Obes Metab 12:623-30. 2010
    ....
  11. doi request reprint Management of diabetes in cardiovascular patients: diabetic heart disease
    R Peter
    Llandough Hospital, Llandough, Cardiff, UK
    Heart 94:369-75. 2008
  12. doi request reprint Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model
    P McEwan
    Cardiff Research Consortium, Cardiff, Wales, UK
    Diabetes Obes Metab 12:431-6. 2010
    ..We therefore sought to ascertain the respective contribution of hypoglycaemia, weight change and improved blood glucose control on second-line therapy options added to metformin...
  13. doi request reprint Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs
    C Ll Morgan
    Department of Epidemiology, Pharmatelligence, Cardiff, UK
    Diabetes Obes Metab 14:424-32. 2012
    ..This study aimed to describe the pattern of weight change in people with type 2 diabetes (T2DM) over time and when using alternative treatment regimens...
  14. doi request reprint Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008
    C J Currie
    Department of Medicine, School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff Medicentre, Cardiff, Wales, UK
    Diabet Med 27:744-52. 2010
    ..A variety of influences determine prescribing behaviour. The purpose of this study was to characterize the pattern of dispensing for glucose-lowering and monitoring in the UK from 2000 to 2008, inclusively...
  15. ncbi request reprint Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus
    M Evans
    Cardiovascular Sciences Research Group, Department of Medicine, University Hospital of Wales, Cardiff, Heath Park, UK
    Eur J Clin Invest 33:231-8. 2003
    ..2 Iu kg-1) and vitamin C 1-g daily. Eight-h lipid and glucose profiles were measured following a fatty meal. Endothelial function (flow-mediated vasodilatation: FMD) and OS were measured at fasting, 4 h and 8 h...
  16. ncbi request reprint The influence of the Pro12Ala mutation of the PPAR-gamma receptor gene on metabolic and clinical characteristics in treatment-naïve patients with type 2 diabetes
    M Ahluwalia
    School of Applied Sciences, University of Wales Institute Cardiff, Cardiff, UK
    Diabetes Obes Metab 4:376-8. 2002
    ..The P12A allele associated with lower fasting plasma glucose but had no influence on HbA1c or BMI. In obese patients (BMI > 29 kg/m2), the P12A substitution associated with elevated total and non-HDL cholesterol levels...